JP7835691B2 - 高シアル化免疫グロブリン - Google Patents

高シアル化免疫グロブリン

Info

Publication number
JP7835691B2
JP7835691B2 JP2022570510A JP2022570510A JP7835691B2 JP 7835691 B2 JP7835691 B2 JP 7835691B2 JP 2022570510 A JP2022570510 A JP 2022570510A JP 2022570510 A JP2022570510 A JP 2022570510A JP 7835691 B2 JP7835691 B2 JP 7835691B2
Authority
JP
Japan
Prior art keywords
igg antibody
reaction mixture
igg
per gram
bis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022570510A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023526421A5 (https=
JP2023526421A (ja
Inventor
シェーク，ジョン
Original Assignee
モメンタ ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モメンタ ファーマシューティカルズ インコーポレイテッド filed Critical モメンタ ファーマシューティカルズ インコーポレイテッド
Publication of JP2023526421A publication Critical patent/JP2023526421A/ja
Publication of JP2023526421A5 publication Critical patent/JP2023526421A5/ja
Application granted granted Critical
Publication of JP7835691B2 publication Critical patent/JP7835691B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01038—Beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase (2.4.1.38)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2022570510A 2020-05-19 2021-05-19 高シアル化免疫グロブリン Active JP7835691B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063026826P 2020-05-19 2020-05-19
US63/026,826 2020-05-19
US202063108741P 2020-11-02 2020-11-02
US63/108,741 2020-11-02
PCT/US2021/033150 WO2021236765A1 (en) 2020-05-19 2021-05-19 Hyper-sialylated immunoglobulin

Publications (3)

Publication Number Publication Date
JP2023526421A JP2023526421A (ja) 2023-06-21
JP2023526421A5 JP2023526421A5 (https=) 2025-04-11
JP7835691B2 true JP7835691B2 (ja) 2026-03-25

Family

ID=78708031

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022570510A Active JP7835691B2 (ja) 2020-05-19 2021-05-19 高シアル化免疫グロブリン

Country Status (11)

Country Link
US (1) US20230192814A1 (https=)
EP (1) EP4153622A4 (https=)
JP (1) JP7835691B2 (https=)
KR (1) KR20230012576A (https=)
CN (1) CN115867571A (https=)
AU (1) AU2021275115A1 (https=)
BR (1) BR112022023334A2 (https=)
CA (1) CA3182136A1 (https=)
CO (1) CO2022016670A2 (https=)
MX (1) MX2022014525A (https=)
WO (1) WO2021236765A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2877589B1 (en) 2012-07-26 2024-03-06 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
WO2014186310A1 (en) 2013-05-13 2014-11-20 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
CA3174533A1 (en) * 2020-03-05 2021-09-10 Momenta Pharmaceuticals, Inc. Methods of making hyper-sialylated immunoglobulin
WO2026014960A1 (ko) * 2024-07-11 2026-01-15 건국대학교 산학협력단 인간으로부터 분리한 형질세포들을 이용한 α-2,6-시알산화 면역글로불린의 제조방법

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005535291A (ja) 2002-03-19 2005-11-24 プラント リサーチ インターナショナル ベスローテン フェンノートシャップ 植物体内のグリカンプロセシングの最適化
US20160108450A1 (en) 2013-05-02 2016-04-21 Momenta Pharmaceutcals, Inc. Sialylated glycoproteins
WO2020077298A1 (en) 2018-10-11 2020-04-16 Momenta Pharmaceuticals, Inc. Treatment with highly silylated igg compositions
JP2023512323A (ja) 2020-02-14 2023-03-24 北京小米移動軟件有限公司 フィードバック方式の指示及び決定方法、装置、記憶媒体
JP2023526527A (ja) 2020-05-19 2023-06-21 モメンタ ファーマシューティカルズ インコーポレイテッド 高シアル化ＩｇＧの調製及び精製

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2805964T3 (es) * 2008-10-29 2021-02-16 Janssen Biotech Inc Composiciones de galactosa alfa (1-3) galactosa
EP2821482A1 (en) * 2013-07-05 2015-01-07 Roche Diagniostics GmbH N-terminally truncated glycosyltransferases
JP6931058B2 (ja) * 2016-12-21 2021-09-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗体のインビトロ糖鎖工学における酵素の再使用
JP2023538400A (ja) * 2020-08-21 2023-09-07 モメンタ ファーマシューティカルズ インコーポレイテッド 高シアル化免疫グロブリン

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005535291A (ja) 2002-03-19 2005-11-24 プラント リサーチ インターナショナル ベスローテン フェンノートシャップ 植物体内のグリカンプロセシングの最適化
US20160108450A1 (en) 2013-05-02 2016-04-21 Momenta Pharmaceutcals, Inc. Sialylated glycoproteins
WO2020077298A1 (en) 2018-10-11 2020-04-16 Momenta Pharmaceuticals, Inc. Treatment with highly silylated igg compositions
JP2023512323A (ja) 2020-02-14 2023-03-24 北京小米移動軟件有限公司 フィードバック方式の指示及び決定方法、装置、記憶媒体
JP2023526527A (ja) 2020-05-19 2023-06-21 モメンタ ファーマシューティカルズ インコーポレイテッド 高シアル化ＩｇＧの調製及び精製

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Barb, A. W. et al.，NMR Characterization of Immunoglobulin G Fc Glycan Motion on Enzymatic Sialylation，Biochemistry，2012年，vol.51，p.4618-4626
Washburn, N. et al.，Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity，PNAS，2015年，p.E1297-E1306

Also Published As

Publication number Publication date
CO2022016670A2 (es) 2022-11-29
US20230192814A1 (en) 2023-06-22
CN115867571A (zh) 2023-03-28
KR20230012576A (ko) 2023-01-26
BR112022023334A2 (pt) 2022-12-20
CA3182136A1 (en) 2021-11-25
AU2021275115A1 (en) 2022-11-10
WO2021236765A1 (en) 2021-11-25
JP2023526421A (ja) 2023-06-21
MX2022014525A (es) 2022-12-13
EP4153622A4 (en) 2024-06-12
EP4153622A1 (en) 2023-03-29

Similar Documents

Publication Publication Date Title
JP7835691B2 (ja) 高シアル化免疫グロブリン
US20250195643A1 (en) Treatment with highly siaylated igg compositions
US20230357813A1 (en) Hypersialylated immunoglobulin
JP7753236B2 (ja) グリカンのシアリル化のための酵素
US20230374062A1 (en) Methods of making hyper-sialylated immunoglobulin
US20230193339A1 (en) Preparation and Purification of Hypersialylated IGG
EP2764020B1 (en) Process for antibody g1 glycoform production
ES2805964T3 (es) Composiciones de galactosa alfa (1-3) galactosa
RU2844159C1 (ru) Получение и очистка гиперсиалилированного igg
RU2849059C1 (ru) Ферменты для сиалилирования гликанов
RU2847105C1 (ru) Способы получения гиперсиалилированного иммуноглобулина
US20230417762A1 (en) Sialylated glycoproteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240520

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250520

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250815

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251120

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260217

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260312

R150 Certificate of patent or registration of utility model

Ref document number: 7835691

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150